EQT Future, EQT’s new impact-driven longer-hold investment strategy, and ATHOS have invested in SHL Medical alongside a consortium of other coinvestors.
Headquartered in Switzerland, SHL Medical is a major provider of drug-delivery solutions. The company serves as a partner to global pharmaceutical and biotech companies in the development and production of medical autoinjectors, which allow patients to safely self-administer medication at home. SHL Medical has a global presence with offices and operations in Europe, Asia and the United States.
The consortium will acquire a minority share of the company from EQT’s Equity fund VIII, which will exit the company. Roger Samuelsson, the company’s founder, will remain the majority shareholder.
Since the investment by EQT VIII in 2020, SHL Medical significantly has outperformed its business plan, having upgraded its manufacturing and commercial capabilities while focusing on digitalization. It has recently won sev
